Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$0.50
$0.48
$0.36
$7.31
$7.46M1.9876,300 shsN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.17
$1.07
$1.78
$40.66
$35.28M1.4620,672 shs81,520 shs
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$0.72
$0.72
$0.55
$1.45
$23.72M-0.57504,272 shsN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
$7.34
+2.5%
$7.48
$4.56
$13.79
$29.26M0.1512,138 shs1,499 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00%+12.50%+14.71%-18.75%+48.10%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
0.00%0.00%0.00%+6.44%-42.81%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
+0.11%+1.30%+3.39%-6.94%-24.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
2.7278 of 5 stars
3.54.00.00.01.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
2.33
Hold$0.9531.83% Upside
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
3.00
Buy$37.50410.90% Upside

Current Analyst Ratings Breakdown

Latest AYLA, INKT, CRTX, and CYTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$3.51M2.13N/AN/A$2.45 per share0.21
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$870.73K27.24N/AN/A$0.21 per share3.43
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/AN/AN/AN/A($5.23) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$22.46M-$2.52N/AN/AN/AN/AN/A-189.14%8/12/2025 (Estimated)

Latest AYLA, INKT, CRTX, and CYTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$0.61-$0.70-$0.09-$0.70N/AN/A
3/18/2025Q4 2024
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$0.50-$0.62-$0.12-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/A
2.28
2.28
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/A
0.17
0.16
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/A
0.89
0.89

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
22.10%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
68.55%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
2.87%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
3.60%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
29.78%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
22.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
3514.82 million14.29 millionNot Optionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
932.92 million23.12 millionNo Data
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
303.99 million3.15 millionNo Data

Recent News About These Companies

MiNK Therapeutics (NASDAQ:INKT) Shares Up 0.1% - Still a Buy?
Q1 2025 Mink Therapeutics Inc Earnings Call
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c)
Q4 2024 Mink Therapeutics Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:AYLA

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.17 0.00 (0.00%)
As of 06/9/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Cyclo Therapeutics stock logo

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)
As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

MiNK Therapeutics stock logo

MiNK Therapeutics NASDAQ:INKT

$7.34 +0.18 (+2.51%)
Closing price 03:58 PM Eastern
Extended Trading
$7.18 -0.17 (-2.25%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.